Exited position

George Soros’s United Therapeutics Corp Del (UTHR) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Soros Fund ManagementVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ2 2006Earliest verified positive filing snapshot
Latest statusExited positionBased on the latest supported relationship state
Peak shares187.30KHighest verified quarter-end share count
Quarters reported9Verified quarters with shares above zero
What happened?

Soros Fund Management first reported United Therapeutics Corp Del in Q2 2006. The reported position was increased and reduced across later filings. The latest verified relationship event shows that Soros Fund Management sold the entire position in Q2 2024, and the stock is no longer reported in the latest verified portfolio.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2024
Sold the entire position−1.05K shares · No shares reported at quarter-end
Q1 2024
New position+1.05K shares · 1.05K shares reported
Filing context

Quarter-end price $229.72 · Estimated holding basis $229.72

Q1 2016
Sold the entire position−4.40K shares · No shares reported at quarter-end
Q4 2015
New position+4.40K shares · 4.40K shares reported
Filing context

Quarter-end price $156.59 · Estimated holding basis $156.59

Q3 2011
Sold the entire position−100.20K shares · No shares reported at quarter-end
Q2 2011
Sold 7.0% of the position−7.50K shares · 100.20K shares remained
Filing context

Quarter-end price $55.10 · Estimated holding basis $66.18

Portfolio importance

How important was United Therapeutics Corp Del in Soros Fund Management’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight0.0%Q1 2024
Last reported rank#164of 164 reported positions
Peak portfolio weight0.3%Q4 2007
Best historical rank#64Q4 2007
At peak importanceQ4 2007
UTHR
0.3%
Largest holding
10.8%
Cross-investor discovery

Who else owns United Therapeutics Corp Del?

Also reported by 2 other tracked investors in their latest verified filings.

Ray DalioBridgewater Associates, LP
UTHR0.2% of reported portfolio
Joel GreenblattGotham Asset Management
UTHR0.1% of reported portfolio
Explore United Therapeutics Corp Del across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$497.112026-09-11

Market context only; not an investor transaction price.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Soros Fund Management LLC’s Form 13F disclosures—not George Soros’s personal brokerage account. George Soros founded the firm; its current CEO and chief investment officer is Dawn Fitzpatrick. Form 13F does not reveal exact trade dates, execution prices or the purpose of an option position.